{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T17:39:40Z","timestamp":1787506780732,"version":"build-2736575974"},"reference-count":58,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinica Chimica Acta"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.cca.2026.120910","type":"journal-article","created":{"date-parts":[[2026,2,15]],"date-time":"2026-02-15T23:30:59Z","timestamp":1771198259000},"page":"120910","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["CYFRA 21-1 as a circulating biomarker in non-small cell lung cancer"],"prefix":"10.1016","volume":"586","author":[{"given":"Neelam","family":"Singla","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kavita","family":"Goyal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pawan","family":"Goud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vaishali","family":"Goel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Avijit","family":"Mazumder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.P.","family":"Hemalatha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vijayakumar","family":"Sachidananda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaurav","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sachin Kumar","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kamal","family":"Dua","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian Gregory George","family":"Oliver","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.cca.2026.120910_bb0005","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J. Clin."},{"issue":"13","key":"10.1016\/j.cca.2026.120910_bb0010","doi-asserted-by":"crossref","DOI":"10.3390\/cancers16132338","article-title":"Identification and application of emerging biomarkers in treatment of non-small-cell lung cancer: systematic review","volume":"16","author":"Restrepo","year":"2024","journal-title":"Cancers (Basel)"},{"issue":"6","key":"10.1016\/j.cca.2026.120910_bb0015","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14061384","article-title":"Deciphering tumour heterogeneity: from tissue to liquid biopsy","volume":"14","author":"Gilson","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"1","key":"10.1016\/j.cca.2026.120910_bb0020","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1038\/s41392-024-01823-2","article-title":"Tumor biomarkers for diagnosis, prognosis and targeted therapy","volume":"9","author":"Zhou","year":"2024","journal-title":"Signal Transduct. Target. Ther."},{"issue":"1","key":"10.1016\/j.cca.2026.120910_bb0025","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1186\/1465-9921-6-78","article-title":"Serum biomarkers in interstitial lung diseases","volume":"6","author":"Tzouvelekis","year":"2005","journal-title":"Respir. Res."},{"issue":"5","key":"10.1016\/j.cca.2026.120910_bb0030","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1016\/0959-8049(94)90528-2","article-title":"CYFRA 21-1, a sensitive and specific new tumour marker for squamous cell lung cancer. Report of the first European multicentre evaluation","volume":"30","author":"Rastel","year":"1994","journal-title":"Eur. J. Cancer"},{"issue":"11","key":"10.1016\/j.cca.2026.120910_bb0035","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1038\/sj.bjc.6601851","article-title":"CYFRA 21-1 is a prognostic determinant in non-small-cell lung cancer: results of a meta-analysis in 2063 patients","volume":"90","author":"Pujol","year":"2004","journal-title":"Br. J. Cancer"},{"issue":"1","key":"10.1016\/j.cca.2026.120910_bb0040","doi-asserted-by":"crossref","first-page":"9444","DOI":"10.1038\/srep09444","article-title":"Prognostic value of serum cytokeratin 19 fragments (Cyfra 21-1) in patients with non-small cell lung cancer","volume":"5","author":"Xu","year":"2015","journal-title":"Sci. Rep."},{"key":"10.1016\/j.cca.2026.120910_bb0045","article-title":"A deeper evaluation of cytokeratin fragment 21-1 as a lung cancer tumor marker and comparison of different assays","volume":"23","author":"Rowe","year":"2025","journal-title":"Biosensors and Bioelectronics: X"},{"issue":"18","key":"10.1016\/j.cca.2026.120910_bb0050","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1016\/j.clinbiochem.2017.08.015","article-title":"The investigation of interferences in immunoassay","volume":"50","author":"Ward","year":"2017","journal-title":"Clin. Biochem."},{"issue":"5","key":"10.1016\/j.cca.2026.120910_bb0055","first-page":"807","article-title":"Reference change values","volume":"50","author":"Fraser","year":"2011","journal-title":"Clin. Chem. Lab. Med."},{"issue":"4","key":"10.1016\/j.cca.2026.120910_bb0060","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a018275","article-title":"Types I and II keratin intermediate filaments","volume":"10","author":"Jacob","year":"2018","journal-title":"Cold Spring Harb. Perspect. Biol."},{"issue":"1","key":"10.1016\/j.cca.2026.120910_bb0065","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/S0169-5002(00)00125-2","article-title":"Mechanisms of the release of CYFRA21-1 in human lung cancer cell lines","volume":"30","author":"Dohmoto","year":"2000","journal-title":"Lung Cancer"},{"issue":"2","key":"10.1016\/j.cca.2026.120910_bb0070","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1177\/172460089400900203","article-title":"Lung cancer-associated keratin 19 fragments: development and biochemical characterisation of the new serum assay Enzymun-test CYFRA 21-1","volume":"9","author":"Bodenm\u00fcller","year":"1994","journal-title":"Int. J. Biol. Markers"},{"issue":"52","key":"10.1016\/j.cca.2026.120910_bb0075","doi-asserted-by":"crossref","first-page":"33197","DOI":"10.1074\/jbc.272.52.33197","article-title":"Apoptosis generates stable fragments of human type I keratins","volume":"272","author":"Ku","year":"1997","journal-title":"J. Biol. Chem."},{"issue":"4","key":"10.1016\/j.cca.2026.120910_bb0080","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1002\/jcb.10173","article-title":"Release of cytokeratin-18 and -19 fragments (TPS and CYFRA 21-1) into the extracellular space during apoptosis","volume":"85","author":"Sheard","year":"2002","journal-title":"J. Cell. Biochem."},{"issue":"2","key":"10.1016\/j.cca.2026.120910_bb0085","first-page":"441","article-title":"CYFRA 21-1 is released in TNF-alpha-induced apoptosis in the hepatocellular carcinoma cell line HuH-7","volume":"21","author":"Wu","year":"2002","journal-title":"Int. J. Oncol."},{"issue":"6","key":"10.1016\/j.cca.2026.120910_bb0090","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1080\/00365510701282326","article-title":"Serum tumour markers in patients with chronic kidney disease","volume":"67","author":"Xiaofang","year":"2007","journal-title":"Scand. J. Clin. Lab. Invest."},{"issue":"4","key":"10.1016\/j.cca.2026.120910_bb0095","doi-asserted-by":"crossref","DOI":"10.1515\/almed-2020-0005","article-title":"CYFRA 21-1 in patients with suspected cancer: evaluation of an optimal cutoff to assess the diagnostic efficacy and prognostic value","volume":"1","author":"Garcia-Valdecasas Gayo","year":"2020","journal-title":"Advances in Laboratory Medicine \/ Avances en Medicina de Laboratorio"},{"issue":"1","key":"10.1016\/j.cca.2026.120910_bb0100","doi-asserted-by":"crossref","first-page":"82","DOI":"10.3343\/alm.2023.43.1.82","article-title":"Establishment of reference intervals of cytokeratin 19 fragment antigen 21-1 in Korean adults","volume":"43","author":"Yoon","year":"2023","journal-title":"Ann. Lab. Med."},{"issue":"11","key":"10.1016\/j.cca.2026.120910_bb0105","article-title":"SCCA and CYFRA 21-1 reference intervals for apparently healthy Chinese adults: a multicenter cross-sectional study","volume":"70","author":"Jiang","year":"2024","journal-title":"Clin. Lab."},{"issue":"4","key":"10.1016\/j.cca.2026.120910_bb0110","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1515\/cclm-2023-0795","article-title":"Quantification of the lung cancer tumor marker CYFRA 21-1 using protein precipitation, immunoaffinity bottom-up LC-MS\/MS","volume":"62","author":"Genet","year":"2024","journal-title":"Clin. Chem. Lab. Med."},{"issue":"36","key":"10.1016\/j.cca.2026.120910_bb0115","doi-asserted-by":"crossref","first-page":"31916","DOI":"10.1021\/acsomega.2c02763","article-title":"Assay performance of a label-free, solution-phase CYFRA 21-1 determination","volume":"7","author":"Kussrow","year":"2022","journal-title":"ACS Omega"},{"issue":"6","key":"10.1016\/j.cca.2026.120910_bb0120","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1021\/acscombsci.9b00022","article-title":"Compensated interferometry measures of CYFRA 21\u20131 improve diagnosis of lung Cancer","volume":"21","author":"Kammer","year":"2019","journal-title":"ACS Comb. Sci."},{"issue":"1","key":"10.1016\/j.cca.2026.120910_bb0125","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1038\/s41598-017-01250-0","article-title":"Multifunctional substrate of label-free electrochemical immunosensor for ultrasensitive detection of cytokeratins antigen 21-1","volume":"7","author":"Wang","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.cca.2026.120910_bb0130","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.talanta.2017.09.020","article-title":"A sensitive label-free electrochemical immunosensor for detection of cytokeratin 19 fragment antigen 21-1 based on 3D graphene with gold nanopaticle modified electrode","volume":"178","author":"Zeng","year":"2018","journal-title":"Talanta"},{"issue":"4","key":"10.1016\/j.cca.2026.120910_bb0135","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1007\/s00604-020-04677-x","article-title":"Electrochemiluminescence immunosensor for cytokeratin fragment antigen 21-1 detection using electrochemically mediated atom transfer radical polymerization","volume":"188","author":"Jian","year":"2021","journal-title":"Microchim. Acta"},{"key":"10.1016\/j.cca.2026.120910_bb0140","doi-asserted-by":"crossref","first-page":"1251595","DOI":"10.3389\/fbioe.2023.1251595","article-title":"Highly sensitive detection of CYFRA21-1 with a SERS sensing platform based on the MBs enrichment strategy and antibody-DNA-mediated CHA amplification","volume":"11","author":"Bao","year":"2023","journal-title":"Front. Bioeng. Biotechnol."},{"key":"10.1016\/j.cca.2026.120910_bb0145","doi-asserted-by":"crossref","DOI":"10.1016\/j.snr.2024.100198","article-title":"Hypersensitive detection of CYFRA21-1 by SERS dual antibody sandwich method","volume":"7","author":"Ge","year":"2024","journal-title":"Sensors and Actuators Reports"},{"issue":"12","key":"10.1016\/j.cca.2026.120910_bb0150","article-title":"Enhanced analytical performance in CYFRA 21-1 detection using lateral flow assay with magnetic bioconjugates: integration and comparison of magnetic and optical registration","volume":"14","author":"Skirda","year":"2024","journal-title":"Biosensors (Basel)"},{"issue":"s1","key":"10.1016\/j.cca.2026.120910_bb0155","doi-asserted-by":"crossref","first-page":"S15","DOI":"10.3233\/TUB-220013","article-title":"Pre-analytical stability of the CEA, CYFRA 21.1, NSE, CA125 and HE4 tumor markers","volume":"46","author":"Canki","year":"2024","journal-title":"Tumour Biol."},{"issue":"1","key":"10.1016\/j.cca.2026.120910_bb0160","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1186\/s12890-023-02650-x","article-title":"Variability of serum CYFRA 21-1 and its susceptibility to clinical characteristics in individuals without cancer: a 4-year retrospective analysis","volume":"23","author":"Minamibata","year":"2023","journal-title":"BMC Pulm. Med."},{"issue":"4","key":"10.1016\/j.cca.2026.120910_bb0165","doi-asserted-by":"crossref","first-page":"e461","DOI":"10.5301\/ijbm.5000278","article-title":"Reference limits for chromogranin a, CYFRA 21-1, CA 125, CA 19-9 and carcinoembryonic antigen in patients with chronic kidney disease","volume":"32","author":"Mikkelsen","year":"2017","journal-title":"Int. J. Biol. Markers"},{"key":"10.1016\/j.cca.2026.120910_bb0170","doi-asserted-by":"crossref","first-page":"1072531","DOI":"10.3389\/fonc.2022.1072531","article-title":"Changes in lung cancer-related serum tumor markers in patients with chronic kidney disease and determination of upper reference limit","volume":"12","author":"Miao","year":"2022","journal-title":"Front. Oncol."},{"issue":"12","key":"10.1016\/j.cca.2026.120910_bb0175","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1164\/rccm.202107-1769OC","article-title":"CYFRA 21-1 predicts progression in idiopathic pulmonary fibrosis: a prospective longitudinal analysis of the PROFILE cohort","volume":"205","author":"Molyneaux","year":"2022","journal-title":"Am. J. Respir. Crit. Care Med."},{"issue":"35","key":"10.1016\/j.cca.2026.120910_bb0180","doi-asserted-by":"crossref","DOI":"10.3346\/jkms.2021.36.e224","article-title":"Word embedding reveals Cyfra 21-1 as a biomarker for chronic obstructive pulmonary disease","volume":"36","author":"Heo","year":"2021","journal-title":"J. Korean Med. Sci."},{"issue":"68","key":"10.1016\/j.cca.2026.120910_bb0185","doi-asserted-by":"crossref","first-page":"10060","DOI":"10.1039\/C9CC03620B","article-title":"Quantification of CYFRA 21-1 and a CYFRA 21-1\u2013anti-CYFRA 21-1 autoantibody immune complex for detection of early stage lung cancer","volume":"55","author":"Song","year":"2019","journal-title":"Chem. Commun."},{"issue":"8","key":"10.1016\/j.cca.2026.120910_bb0190","doi-asserted-by":"crossref","first-page":"2569","DOI":"10.31557\/APJCP.2021.22.8.2569","article-title":"Cross-sectional study to establish the utility of serum tumor markers in the diagnosis of lung Cancer","volume":"22","author":"Mehta","year":"2021","journal-title":"Asian Pac. J. Cancer Prev."},{"issue":"2","key":"10.1016\/j.cca.2026.120910_bb0195","doi-asserted-by":"crossref","first-page":"935","DOI":"10.21873\/anticanres.11402","article-title":"CYFRA 21-1 as a predictive marker for non-small cell lung Cancer treated with Pemetrexed-based chemotherapy","volume":"37","author":"Sone","year":"2017","journal-title":"Anticancer Res"},{"issue":"4","key":"10.1016\/j.cca.2026.120910_bb0200","doi-asserted-by":"crossref","first-page":"2053","DOI":"10.21873\/anticanres.14974","article-title":"Prognostic role for CYFRA 21-1 in patients with advanced-stage NSCLC treated with bevacizumab plus chemotherapy","volume":"41","author":"Svaton","year":"2021","journal-title":"Anticancer Res"},{"issue":"52","key":"10.1016\/j.cca.2026.120910_bb0205","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000005748","article-title":"CYFRA 21-1 is an early predictor of chemotherapeutic effectiveness in advanced nonsmall cell lung cancer: an observational study","volume":"95","author":"Zhao","year":"2016","journal-title":"Medicine (Baltimore)"},{"issue":"1","key":"10.1016\/j.cca.2026.120910_bb0210","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1186\/s12967-019-1828-0","article-title":"The role of CEA, CYFRA21-1 and NSE in monitoring tumor response to Nivolumab in advanced non-small cell lung cancer (NSCLC) patients","volume":"17","author":"Dal Bello","year":"2019","journal-title":"J. Transl. Med."},{"issue":"21","key":"10.1016\/j.cca.2026.120910_bb0215","doi-asserted-by":"crossref","DOI":"10.3390\/cancers16213712","article-title":"Serum CYFRA 21-1 as a prognostic marker in non-small-cell lung Cancer patients treated with immune checkpoint inhibitors","volume":"16","author":"Miyadera","year":"2024","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.cca.2026.120910_bb0220","article-title":"CEA and CYFRA 21-1 as prognostic biomarker and as a tool for treatment monitoring in advanced NSCLC treated with immune checkpoint inhibitors","volume":"12","author":"Dall'Olio","year":"2020","journal-title":"Ther. Adv. Med. Oncol."},{"issue":"3","key":"10.1016\/j.cca.2026.120910_bb0225","doi-asserted-by":"crossref","first-page":"227","DOI":"10.21037\/tlcr.2019.06.08","article-title":"Carcinoembryonic antigen and CYFRA 21-1 responses as prognostic factors in advanced non-small cell lung cancer","volume":"8","author":"Yoshimura","year":"2019","journal-title":"Transl Lung Cancer Res"},{"issue":"42","key":"10.1016\/j.cca.2026.120910_bb0230","doi-asserted-by":"crossref","DOI":"10.18632\/oncotarget.17611","article-title":"Postoperative CYFRA 21-1 and CEA as prognostic factors in patients with stage I pulmonary adenocarcinoma","volume":"8","author":"He","year":"2017","journal-title":"Oncotarget"},{"issue":"6","key":"10.1016\/j.cca.2026.120910_bb0235","doi-asserted-by":"crossref","first-page":"1986","DOI":"10.21037\/tlcr-2024-1180","article-title":"Utility of serum CYFRA 21-1 as a prognostic biomarker in ALK-positive non-small cell lung cancer treated with ALK-TKIs: a retrospective cohort study","volume":"14","author":"Sawada","year":"2025","journal-title":"Translational Lung Cancer Research"},{"issue":"s1","key":"10.1016\/j.cca.2026.120910_bb0240","doi-asserted-by":"crossref","first-page":"S163","DOI":"10.3233\/TUB-220042","article-title":"CYFRA 21-1, CA 125 and CEA provide additional prognostic value in NSCLC patients with stable disease at first CT scan","volume":"46","author":"Muley","year":"2024","journal-title":"Tumour Biol."},{"issue":"8","key":"10.1016\/j.cca.2026.120910_bb0245","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.21037\/tlcr-24-190","article-title":"CYFRA 21-1 predicts efficacy of combined chemoimmunotherapy in patients with advanced non-small cell lung cancer: a prospective observational study","volume":"13","author":"Kataoka","year":"2024","journal-title":"Translational Lung Cancer Research"},{"issue":"1","key":"10.1016\/j.cca.2026.120910_bb0250","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.lungcan.2013.01.002","article-title":"Diagnostic value of CEA and CYFRA 21-1 tumor markers in primary lung cancer","volume":"80","author":"Okamura","year":"2013","journal-title":"Lung Cancer"},{"issue":"2","key":"10.1016\/j.cca.2026.120910_bb0255","doi-asserted-by":"crossref","DOI":"10.1002\/hsr2.1107","article-title":"Establishment and validation of reference intervals for tumor markers (AFP, CEA, CA19-9, CA15-3, CA125, PSA, HE4, Cyfra 21-1, and ProGRP) in primary care centers in Korea: a cross-sectional retrospective study","volume":"6","author":"Nah","year":"2023","journal-title":"Health Sci Rep"},{"key":"10.1016\/j.cca.2026.120910_bb0260","doi-asserted-by":"crossref","first-page":"12339","DOI":"10.3389\/bjbs.2024.12339","article-title":"The role and limitations of the reference interval within clinical chemistry and its reliability for disease detection","volume":"81","author":"Timbrell","year":"2024","journal-title":"Br. J. Biomed. Sci."},{"issue":"4","key":"10.1016\/j.cca.2026.120910_bb0265","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1515\/cclm-2021-0769","article-title":"Biological variation, reference change values and index of individuality of GDF-15","volume":"60","author":"Sithiravel","year":"2022","journal-title":"Clin. Chem. Lab. Med."},{"key":"10.1016\/j.cca.2026.120910_bb0270","doi-asserted-by":"crossref","first-page":"4295","DOI":"10.2147\/OTT.S145036","article-title":"Improvement of survival for non-small cell lung cancer over time","volume":"10","author":"Xia","year":"2017","journal-title":"Onco. Targets Ther."},{"key":"10.1016\/j.cca.2026.120910_bb0275","doi-asserted-by":"crossref","first-page":"72","DOI":"10.3109\/00365519509090568","article-title":"CYFRA 21-1--clinical applications and analytical requirements","volume":"221","author":"Ebert","year":"1995","journal-title":"Scand. J. Clin. Lab. Invest. Suppl."},{"key":"10.1016\/j.cca.2026.120910_bb0280","doi-asserted-by":"crossref","DOI":"10.7717\/peerj.19240","article-title":"Tumor marker elevations in chronic kidney disease: a retrospective study","volume":"13","author":"You","year":"2025","journal-title":"PeerJ"},{"issue":"3","key":"10.1016\/j.cca.2026.120910_bb0285","doi-asserted-by":"crossref","DOI":"10.4103\/ijc.IJC_490_20","article-title":"Diagnostic value of tumor markers CEA, CYFRA21-1, SCC, and proGRP in detecting lung cancer","volume":"61","author":"Xu","year":"2024","journal-title":"Indian J. Cancer"},{"issue":"1","key":"10.1016\/j.cca.2026.120910_bb0290","doi-asserted-by":"crossref","first-page":"1","DOI":"10.7150\/jca.78574","article-title":"Circulating tumor DNA correlates with lactate dehydrogenase, CYFRA 21-1, and CRP levels in patients with advanced NSCLC","volume":"14","author":"Buresova","year":"2023","journal-title":"J. Cancer"}],"container-title":["Clinica Chimica Acta"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0009898126000926?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0009898126000926?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T08:24:51Z","timestamp":1784017491000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0009898126000926"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":58,"alternative-id":["S0009898126000926"],"URL":"https:\/\/doi.org\/10.1016\/j.cca.2026.120910","relation":{},"ISSN":["0009-8981"],"issn-type":[{"value":"0009-8981","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"CYFRA 21-1 as a circulating biomarker in non-small cell lung cancer","name":"articletitle","label":"Article Title"},{"value":"Clinica Chimica Acta","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cca.2026.120910","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"120910"}}